Michael Stadler
Overview
Explore the profile of Michael Stadler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
128
Citations
3296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hupe H, Wienecke C, Bartels S, Schipper E, Lessmann J, Lasch A, et al.
Hemasphere
. 2025 Mar;
9(3):e70097.
PMID: 40066001
Isolated extramedullary manifestations (IEM) of acute myeloid leukemia (AML) are recurrent events, especially following allogeneic hematopoietic cell transplantation (alloHCT). To date, measurable residual disease (MRD) assessment for this difficult-to-treat patient...
2.
Schroeder T, Flossdorf S, Schuh C, Pabst C, Stadler M, Schetelig J, et al.
Transplant Cell Ther
. 2025 Mar;
PMID: 40058648
Mutations in isocitrate dehydrogenase 1 and 2 genes (IDH1 and IDH2) are found in 15% to 20% of patients with acute myeloid leukemia (AML). IDH inhibitors have been introduced as...
3.
Stadler M, Zhao S, Bowes J
Best Pract Res Clin Rheumatol
. 2024 Sep;
38(4):101982.
PMID: 39223061
Spondyloarthropathies (SpA), including ankylosing spondylitis (AS) and psoriatic arthritis (PsA), have been shown to have a substantial genetic predisposition based on heritability estimates derived from family studies and genome-wide association...
4.
Wienecke C, Heida B, Venturini L, Gabdoulline R, Kruger K, Teich K, et al.
Blood
. 2024 Apr;
144(3):296-307.
PMID: 38669617
Patients with acute myeloid leukemia (AML) who experience relapse following allogeneic hematopoietic cell transplantation (alloHCT) face unfavorable outcomes regardless of the chosen relapse treatment. Early detection of relapse at the...
5.
Hum R, Sharma S, Stadler M, Viatte S, Ho P, Nair N, et al.
Future Healthc J
. 2024 Feb;
10(Suppl 3):24-25.
PMID: 38406688
No abstract available.
6.
Hum R, Sharma S, Stadler M, Viatte S, Ho P, Nair N, et al.
Arthritis Rheumatol
. 2023 Nov;
76(5):696-703.
PMID: 38010198
Objective: There is growing evidence that genetic data are of benefit in the rheumatology outpatient setting by aiding early diagnosis. A genetic probability tool (G-PROB) has been developed to aid...
7.
Donkor G, Anderson G, Stadler M, Tawiah P, Orellano C, Edwards K, et al.
mSphere
. 2023 Aug;
8(5):e0019023.
PMID: 37646510
The rapid dissemination of antibiotic resistance combined with the decline in the discovery of novel antibiotics represents a major challenge for infectious disease control that can only be mitigated by...
8.
Hamzaraj K, Angjeliu S, Knopf P, Stadler M, Zbucki K, Kastrati L, et al.
Front Cardiovasc Med
. 2023 Aug;
10:1168360.
PMID: 37608818
Primary pulmonary artery hypertension (PAH) is a clinical diagnosis that requires the exclusion of other underlying causes of pulmonary hypertension (PH). Increased pulmonary artery (PA) pressure and subsequent right ventricular...
9.
Teich K, Stadler M, Gabdoulline R, Kandarp J, Wienecke C, Heida B, et al.
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568726
Donor lymphocyte infusions (DLIs) can directly target leukemic cells through a graft-versus-leukemia effect and play a key role in the prevention and management of relapse after allogeneic hematopoietic cell transplantation...
10.
Stadler M, Hambach L, Dammann E, Diedrich H, Kamal H, Hamwi I, et al.
Ann Hematol
. 2023 Jul;
102(9):2529-2542.
PMID: 37490114
Therapeutic donor lymphocyte infusions (tDLI) are used to reinforce the graft-versus-leukemia (GvL) effect in relapse after allogeneic stem cell transplantation (alloSCT). In contrast, the role of prophylactic DLI (proDLI) in...